Vertex (VRTX -7.3%) shares sink a day after rising 4% on better-than-expected earnings driven by...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex (VRTX -7.3%) shares sink a day after rising 4% on better-than-expected earnings driven by sales of its Incivek hepatitis C drug. But today, Goldman Sachs and Cowen both downgrade the stock to Neutral from Buy based on VRTX's 2012 guidance in its conference call, while still viewing the company as high quality with innovative R&D.